AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has received acceptance from NYSE American for its compliance plan. The exchange has granted AEON until August 3, 2026 to meet minimum market capitalization and stockholders' equity requirements under Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.
During this period, AEON will undergo periodic reviews to assess progress toward compliance goals. If the company fails to regain compliance by the deadline or doesn't show sufficient progress, NYSE American may initiate delisting proceedings.
AEON Biopharma (NYSE: AEON), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti a base di tossina botulinica, ha ottenuto l'approvazione da parte di NYSE American per il suo piano di conformità. La borsa ha concesso ad AEON tempo fino al 3 agosto 2026 per soddisfare i requisiti minimi di capitalizzazione di mercato e patrimonio netto previsti dalle Sezioni 1003(a)(i), (ii) e (iii) della Guida per le Società di NYSE American.
Durante questo periodo, AEON sarà sottoposta a revisioni periodiche per valutare i progressi verso gli obiettivi di conformità. Se l'azienda non riuscirà a rientrare nei parametri entro la scadenza o non dimostrerà progressi sufficienti, NYSE American potrà avviare le procedure di esclusione dalla quotazione.
AEON Biopharma (NYSE: AEON), una compañía biofarmacéutica en etapa clínica que desarrolla tratamientos con toxina botulínica, ha recibido la aceptación de NYSE American para su plan de cumplimiento. La bolsa ha otorgado a AEON hasta el 3 de agosto de 2026 para cumplir con los requisitos mínimos de capitalización de mercado y patrimonio neto según las Secciones 1003(a)(i), (ii) y (iii) de la Guía para Compañías de NYSE American.
Durante este período, AEON será sometida a revisiones periódicas para evaluar el progreso hacia los objetivos de cumplimiento. Si la compañía no logra recuperar el cumplimiento antes de la fecha límite o no muestra un progreso suficiente, NYSE American podrá iniciar procedimientos de exclusión de cotización.
AEON Biopharma (NYSE: AEON)는 보툴리눔 톡신 치료제를 개발하는 임상 단계의 생명공학 회사로, NYSE American으로부터 준수 계획 승인을 받았습니다. 거래소는 AEON에게 NYSE American 회사 가이드의 1003(a)(i), (ii), (iii) 조항에 따른 최소 시가총액 및 자본 요건을 충족할 수 있도록 2026년 8월 3일까지 기한을 부여했습니다.
이 기간 동안 AEON은 준수 목표 달성 여부를 평가하기 위해 정기적인 검토를 받게 됩니다. 회사가 기한 내에 준수 상태를 회복하지 못하거나 충분한 진전을 보이지 않으면 NYSE American은 상장 폐지 절차를 시작할 수 있습니다.
AEON Biopharma (NYSE : AEON), une société biopharmaceutique en phase clinique développant des traitements à base de toxine botulique, a obtenu l'acceptation de NYSE American pour son plan de conformité. La bourse a accordé à AEON jusqu'au 3 août 2026 pour satisfaire aux exigences minimales de capitalisation boursière et de capitaux propres conformément aux Sections 1003(a)(i), (ii) et (iii) du guide des sociétés de NYSE American.
Pendant cette période, AEON fera l'objet de contrôles périodiques afin d'évaluer ses progrès vers les objectifs de conformité. Si la société ne parvient pas à se conformer avant la date limite ou ne montre pas de progrès suffisants, NYSE American pourra engager des procédures de radiation.
AEON Biopharma (NYSE: AEON), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Botulinumtoxin-Behandlungen entwickelt, hat von der NYSE American die Annahme seines Compliance-Plans erhalten. Die Börse hat AEON bis zum 3. August 2026 Zeit eingeräumt, um die Mindestanforderungen an Marktkapitalisierung und Eigenkapital gemäß den Abschnitten 1003(a)(i), (ii) und (iii) des NYSE American Company Guide zu erfüllen.
Während dieses Zeitraums wird AEON regelmäßigen Überprüfungen unterzogen, um den Fortschritt bei der Erreichung der Compliance-Ziele zu bewerten. Sollte das Unternehmen die Compliance bis zur Frist nicht wiederherstellen oder keinen ausreichenden Fortschritt zeigen, kann die NYSE American Delisting-Verfahren einleiten.
- NYSE American accepted AEON's compliance plan
- Company granted extended period until August 2026 to regain compliance
- Company currently fails to meet NYSE American minimum market capitalization requirements
- Risk of potential delisting if compliance is not achieved by August 2026
- Company faces stockholders' equity deficiency
IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received notification (the “Acceptance Letter”) from the NYSE American LLC (“NYSE American”) that NYSE American has accepted the Company's previously submitted plan (the “Plan”) to regain compliance with NYSE American's continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Company Guide”) relating to minimum market capitalization and stockholders' equity.
In the Acceptance Letter, NYSE American granted the Company until August 3, 2026 (the “Plan Period”) to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide during the Plan Period. If the Company does not regain compliance with the NYSE American listing standards by August 3, 2026, or if the Company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance. For example, statements regarding the Company’s ability to execute on the Plan and regain compliance with the continued listing standards are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “plan”, “possible”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “continue” or “could”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON’s future capital requirements; (iii) AEON’s ability to raise financing in the future; (iv) AEON’s ability to maintain the cash balance required to work through our Biosimilar BPD Type 2a meeting with the FDA; (v) AEON’s ability to continue to meet continued stock exchange listing standards; (vi) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vii) AEON’s ability to progress along a 351(k) biosimiliar pathway to allow ABP-450 to be approved as a biosimilar to BOTOX under a single FDA approval; (viii) the outcomes from any meetings or discussions with regulatory authorities; (ix) AEON’s ability to execute on the Plan and regain compliance with the continued listing standards set forth in the Company Guide during the Plan Period; and (x) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.
Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
What is the deadline for AEON Biopharma to regain NYSE American listing compliance?
What happens if AEON fails to meet NYSE American compliance requirements by 2026?
Which NYSE American listing standards does AEON need to comply with?
How will AEON's compliance progress be monitored by NYSE American?
